Mr. Freitas is an accomplished entrepreneur and senior corporate executive who specializes in the convergence of growth, operations, and technology. His extensive knowledge base includes corporate finance and operations, strategic planning, board governance, mergers and acquisitions activity, risk management, and compliance.
Mr. Freitas’ notable accomplishments include setting up the first-ever learning health system for multiple sclerosis (MSPATHS); advising four of the top ten pharma companies on next-generation medical strategies and operations; devising unique market access strategies for three prominent drug launches post-COVID-19; and constructing multiple real-world data and digital strategies for eight of the top ten pharma companies.
Mr. Freitas built a serial acquirer and comprehensive integration capability to create a market-leading bioinformatics business for researchers; democratized DNA sequencing by creating a consumption revenue model for a leading lab services business; designed a SaaS model for a global lab equipment and tools company; created a strategy to pivot a top US retail pharmacy into the primary care market; and spearheaded the total enterprise transformation effort for a Fortune 10 wholesale distributor and a large U.S.-based academic medical center.
Prior to joining A&M, Mr. Freitas served as the Global Lead of Growth and Corporate Strategy in Life Sciences for Accenture (NYSE: ACN). Previously, he was a co-founder of a boutique strategy consulting firm, Axia Ltd., which Accenture acquired in 2015. Following the sale of Axia to Accenture, Mr. Freitas and team joined a young Accenture Strategy and helped build the world’s fourth largest strategy consulting practice. Before that, Mr. Freitas worked as a microbiologist, a food and drug lawyer, and as the head of Corporate Strategy for ARIAD Pharmaceuticals (now part of Takeda).
Mr. Freitas earned a bachelor’s degree from the University of Connecticut and a J.D. from Tulane University. He is a member of the bars of the Commonwealth of Massachusetts and the First Circuit Court of Appeals.
